Xeno Diagnostics, LLC
One of the largest inhibitors to the advancement of translational research is a lack of specific reagents, antibodies, analytes, and support services for those scientists involved in the early stages of research and development using animal models. While great advancements have been made in the field, there is a constant need for the development of these products and services. Xeno Diagnostics’ goal is to accelerate the advancement of translational medicine by providing these often hard-to-find products and services. With an emphasis on xeno-transplantation of tissues and organs, Xeno provides products and services to researchers using Non-human Primate (NHP), Porcine, Bovine, and Human models for their research. Specifically within this area, Xeno has developed strong support services for those people and organizations in need of outsourced Mixed Lymphocyte Reactions, Cytotoxicity Assays, and other cell-based and immunological assays, which are often labor intensive.
Company details
Find locations served, office locations
- Business Type:
- Service provider
- Industry Type:
- Clinical Services
- Market Focus:
- Nationally (across the country)
- Year Founded:
- 2007
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
As many of our clients are looking to move their technology through FDA approval, Xeno has adopted Good Laboratory Practices (GLP) as defined by Title 21 Code of Federal Regulations, part 58. This ensures that the research performed by Xeno Diagnostics can be done in conformance with the regulations necessary for the research to be submitted to the FDA for potential approval (please note, while GLP research originating from Xeno Diagnostics can be submitted to the FDA, this in no way guarantees that the technology will be approved). Xeno Diagnostics is also a high-complexity CLIA accredited laboratory, and is able to perform research under those regulatory requirements as well. For clients in the very early stages of discovery, Xeno can also perform assays in a Research & Development only format, in an effort to keep costs low.
Xeno Diagnostics obtained its high complexity CLIA accreditation in 2008, and through participation in the external inspection process it maintains high standards in laboratory testing. Clients also benefit from Xeno’s related organizational infrastructure including its relationships with IRB’s, patient recruitment organizations, animal product providers (body fluids, tissues, cells), and biorepositories. These collaborations have allowed Xeno to successfully handle a greater variety of projects in a shorter amount of time.
Our Mission
Xeno Diagnostics, LLC, was created for the purpose of improving human health by providing the necessary reagents, materials, and testing services to bridge the gap between animal models and human pathophysiology research, expanding the field of translational medicine.
Our History
Xeno Diagnostics, LLC was established in 2007 with the purpose of providing products and services to aid in the use of pigs in transplantation and basic research. Xeno’s success in establishing ELISA, PCR, cell culture assays, and antibody development led to clients requesting assistance with other cell-based assays utilizing other animal species. To meet those needs, Xeno expanded its focus to meet those needs as well as addressing unique requests from industry, academia, and startup companies. Additional cell based assays were developed to evaluate emerging technologies ranging from implantable tissues and biosynthetic materials to test compounds aimed at treating cancers, virii, and other diseases. Currently available assays include but are not limited to: Mixed Lymphocyte Reactions (MLR’s), Cytotoxicity Assays (CDC/ADCC), Cytokine Release, Receptor Occupancy Assays, and Immunoglobulin Quantification.
Xeno Diagnostics obtained its high complexity CLIA accreditation in 2008, and through participation in the external inspection process it maintains high standards in laboratory testing. Clients also benefit from Xeno’s related organizational infrastructure including its relationships with IRB’s, patient recruitment organizations, animal product providers (body fluids, tissues, cells), and biorepositories. These collaborations have allowed Xeno to successfully handle a greater variety of projects in a shorter amount of time.